Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696849 | 0.83 | GLA (0.74) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL27654424 | 0.83 | MAPK1 (0.65) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL7358861 | 0.83 | LMNA (0.60) | ALDH1A1L3MBTL1MAPK1GAAKDM4E | |
| SCHEMBL17295523 | 0.82 | GLA (0.50) | ALDH1A1KMT2AMEN1GAACYP2D6 | |
| SCHEMBL17291066 | 0.82 | GLA (0.50) | ALDH1A1KMT2AMEN1GAACYP2D6 | |
| SCHEMBL17065052 | 0.81 | L3MBTL1 (0.65) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL334552 | 0.79 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL14697021 | 0.78 | KMT2A (0.72) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL12793846 | 0.78 | KMT2A (0.72) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 | |
| SCHEMBL1832768 | 0.77 | L3MBTL1 (0.72) | ALDH1A1L3MBTL1MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | ALDH1A1 1883/4885L3MBTL1 4438/4885MAPK1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.